Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients

doi:doi:10.1038/sj.bmt.1703880

Bone Marrow Transplantation (2003) 31, 575–578. doi:10.1038/sj.bmt.1703880

Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients

S Nesci¹, O Buffi¹, A Iliescu¹, M Andreani¹ and G Lucarelli²

¹Laboratorio di Ricerca Onco-Ematologico, Dipartimento di Onco Ematologia, Pesaro, Italy
²Unità Operativa di Ematologia, Centro Trapianti di Midollo Osseo di Muraglia, Azienda Ospedaliera S. Salvatore di Pesaro, Italy

Correspondence: Dr S Nesci, Laboratorio di Ricerca Onco Ematologico, Dipartimento di Onco Ematologia, Azienda 'Ospedale San Salvatore', Via Lombroso, Pesaro, Italy

Received 9 May 2002; Accepted 4 December 2002.

Top

Abstract

In order to determine the influence of HA-1 minor histocompatibility antigen mismatch on BMT outcome, we analyzed a pool of 94 thalassemic transplanted patients all selected for the presence of HLA-A^*0201 allele. The HA-1 typing was performed using SSP analysis. All the patients received bone marrow from HLA-identical MLC nonresponsive siblings. As graft-versus-host-disease (GVHD) prophylaxis, all patients received cyclosporin and short methotrexate. Grades II–IV GVHD occurred in five (33.3%) of the 15 patients with recipient HA-1 disparity compared with 14 (17.7%) of the 79 patients without HA-1 disparity. Despite the higher incidence of acute graft-versus-host-disease (aGVHD) in the group of patients with HA-1 incompatibility, these data were not statistically significant. However, it was interesting to observe that no GVHD developed in any of the 15 cases in which the recipient was HA-1 negative and the donor HA-1 positive.